✦ LIBER ✦

Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells

✍ Scribed by Withoff, S; Bijman, M N A; Stel, A J; Delahaye, L; Calogero, A; Jonge, M W A de; Kroesen, B J; Leij, L de

Book ID: 111724483
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 88 KB
Volume: 84
Category: Article
ISSN: 0007-0920
DOI: 10.1054/bjoc.2000.1707

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immune consolidation after stem cell tra

Immune consolidation after stem cell transplant for CD20+ nonhodgkin’s lymphoma using multiple infusions of autologous activated t cells (ATC) with anti-cd3 x anti-cd20 bispecific antibody (CD20Bi) to improve graft-vs-lymphoma effects

✍ L.G. Lum; P. Davol; G. Colvin; R. Rathore; M. Abedi; E. Palushock; A. Olson; T. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Bi20 (fBTA05), a novel trifunctional bis

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

✍ Michael Stanglmaier; Margot Faltin; Peter Ruf; Annette Bodenhausen; Petra Schröd 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 312 KB

## Abstract Trifunctional bispecific antibodies can efficiently mediate tumor cell killing by redirecting T cells and immune accessory cells to the tumor cell. Here, we describe the new trifunctional antibody, Bi20 (FBTA05, anti‐CD20 × anti‐CD3), that connects B cells and T cells __via__ its variab

Targeting Myeloma Stem Cells with T Cell

Targeting Myeloma Stem Cells with T Cells Armed with Anti-CD3 X Anti-CD20 Bispecific Antibody (CD20BI) Prior to ASCT Leads to Development of Anti-Myeloma Immune Responses Post Autologous Stem Cell Transplant That Can Be Boosted with Targeted T Cells

✍ L.G. Lawrence; T. Archana; A. Muneer; A.-K. Zaid; R. Voravit; Z. Jeffrey; A. Loi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Immunotherapy of recurrent B-cell malign

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

✍ Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 278 KB

GF109203X, a Specific PKC Inhibitor, Abr

GF109203X, a Specific PKC Inhibitor, Abrogates Anti-CD3 Antibody-Induced Upregulation of CD4+ T Cell Adhesion to B Cells

✍ Pascale Hauss; Fabienne Mazerolles; Claire Hivroz; Olivia Lecomte; Christlane Ba 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Immunotherapy with FBTA05 (Bi20), a trif

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB